STORM Therapeutics Ltd., a UK-based clinical stage biotechnology company, announced on Wednesday that it has named Marguerite Hutchinson, JD as its new chief business officer.

Hutchinson has more than ten years of extensive experience in heading licensing agreements and collaborations with large, high profile healthcare companies and experience in legal and strategic operations. She has earlier served as the chief operating officer and general counsel of Plexxikon Inc. She has served as the chief executive fficer at Tatara Therapeutics and held the position of chief business officer at Frontier Medicines Corporation.

Jerry McMahon, STORM Therapeutics chief executive officer, said, 'We are excited by the addition of Marguerite to the STORM leadership team as we continue to maximise collaborations for our developing pipeline of products targeting RNA modifying enzymes. Marguerite brings strategic vision to align our business with existing and new shareholders as we advance our current clinical program into additional advanced clinical studies.'